Literature DB >> 3888543

The activity of ceftazidime compared with those of aztreonam, newer cephalosporins and Sch 29482 against nonfermentative gram-negative bacilli.

R F Schell, M Francisco, J A Bihl, J L LeFrock.   

Abstract

The activity of ceftazidime was compared with those of aztreonam, newer cephalosporins and Sch 29482 against nonfermentative gram-negative bacilli. Ceftazidime was consistently more active (MIC less than or equal to 8 micrograms) against the nonfermenters. Only Flavobacterium odoratum, F. spp., Pseudomonas alcaligenes, P. maltophilia and P. stutzeri demonstrated substantial resistance (MIC90 greater than or equal to 64 micrograms) to ceftazidime. Sch 29482 and ceftriaxone also exhibited good activity (MIC90 less than or equal to 8 micrograms) against many of the nonfermenters. The broad activity of ceftazidime, however, makes it a potentially more useful therapeutic agent against these microorganisms.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3888543     DOI: 10.1159/000238334

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  6 in total

1.  Flavimonas oryzihabitans (Pseudomonas oryzihabitans; CDC group Ve-2): an emerging pathogen in peritonitis related to continuous ambulatory peritoneal dialysis?

Authors:  J W Bendig; P J Mayes; D E Eyers; B Holmes; T T Chin
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

Review 2.  In vitro antibacterial effects of cephalosporins.

Authors:  J D Williams; F Moosdeen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  Microbiological characteristics of Weeksella virosa (formerly CDC group IIf) isolated from the human genitourinary tract.

Authors:  J Reina; J Gil; F Salva; J Gomez; P Alomar
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

4.  Incidence of vaginal Weeksella virosa (formerly group IIf).

Authors:  C Mardy; B Holmes
Journal:  J Clin Pathol       Date:  1988-02       Impact factor: 3.411

Review 5.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

6.  Fatal case of Weeksella virosa sepsis.

Authors:  A K Slenker; B D Hess; D L Jungkind; J A DeSimone
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.